US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,489.77

+9.710.66%

Number of Gainers:10

Number of Losers:10

Number of Flat:- -

PE:- -

High:1,493.79

Open:1,479.95

Low:1,472.49

Close:1,480.06

Loading ...

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'

Neumora Therapeutics Shares Down 11.2% Premarket After Johnson & Johnson Stops Studies of Rival Depression Drug

THOMSON REUTERS

Stock Market Drama Highlights Trump's Game Of Chicken With Economy

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint

MT Newswires Live

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

2 Dependable Dividend Stocks That Can Pay You for Life

AstraZeneca announces MATTERHORN trial results

Advantage Solutions Reports Fourth Quarter and 2024 Results: Transformation Initiatives Continue to Strengthen the Company

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS

Berenberg Bank Remains a Hold on Pfizer (PFE)

Legal Challenges and Financial Risks Prompt Sell Rating for Moderna

Warburg Research Remains a Buy on Deutsche Pfandbriefbank (0R9K)

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

The Smartest Dividend Stocks to Buy With $2,000 Right Now

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4568/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1489.7664,"timestamp":1741623264989,"preClose":1480.0557,"halted":0,"volume":51494475,"delay":0,"changeRate":0.006561,"change":9.710693,"pbRate":4.037358,"amount":3006916321.663734,"amplitude":0.014387,"prevYearClose":1274.8187,"fiveDayClose":1475.2046,"twentyDayClose":1354.9427,"turnoverRate":0.00333,"marketCap":1227936376220,"floatMarketCap":1206396968047,"peRate":31.999995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1493.7869,"amplitude":0.014387,"preClose":1480.0557,"low":1472.4934,"pbRate":"4.037358","latestPrice":1489.7671,"volume":51493796,"delay":0,"open":1479.9548,"prevYearClose":1274.8187,"prevWeekClose":1480.0557,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1475.2046,"twentyDayClose":1354.9427,"sixtyDayClose":1302.6017,"secType":"PLATE","market":"US","turnoverRate":0.00333,"peRate":31.999995,"marketCap":1227936376220,"floatMarketCap":1206396968047,"timestamp":1741623264072,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517243109","title":"Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2517243109","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517243109?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:03","pubTimestamp":1741356230,"startTime":"0","endTime":"0","summary":"On Friday, Johnson & Johnson  decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor  antagonist, as an adjunctive treatment for major depressive disorder .The move follows insufficient efficacy in the target patient population. The data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified.In January, Neumora Therapeutics, Inc.’s released data from the Phase 3 KOASTAL-1 Study of navacaprant for major depressive disorder.The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-sberg Depression Rating Scale  total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale  scale.Navacaprant, like aticaprant, is a kappa opioid receptor antagonist. Johnson & Johnsonsays it continues to build on its leadership in Neuroscience.In January, the healthcare giant agreed to acq","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-stops-stage-depression-140350234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0012050646.USD","LU2468319806.SGD","BK4007","LU1244550221.USD","LU1032955483.USD","BK4534","LU0795875086.SGD","IE0002141913.USD","JNJ","LU1674673428.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","NMRA","LU0058720904.USD","LU1059921491.USD","LU0882574055.USD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4568","LU0345769128.USD","LU1221951129.SGD","LU2347655156.SGD","LU0203345920.USD","SSI","LU0203347892.USD","LU2129689605.HKD","LU1057294990.SGD","LU2592432038.USD","IE00BVYPNW00.USD","LU0640476718.USD","SG9999002232.USD","LU1023059063.AUD","LU1066053197.SGD","LU2089984988.USD","LU0889566641.SGD","IE00BDGV0183.EUR","LU1778281490.HKD","IE000M9KFDE8.USD","LU2505996509.AUD","LU0114720955.EUR","IE00B7SZLL34.SGD","BK4504","BK4588","ITCI","LU2129689514.USD","LU2129689431.USD","SG9999001440.SGD","IE0002270589.USD","LU0234570918.USD","IE0034235303.USD"],"gpt_icon":0},{"id":"2517433745","title":"Neumora Therapeutics Shares Down 11.2% Premarket After Johnson & Johnson Stops Studies of Rival Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517433745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517433745?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:58","pubTimestamp":1741355935,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1929549753.HKD","LU1061106388.HKD","LU0114720955.EUR","IE00BSNM7G36.USD","IE00B4R5TH58.HKD","LU1732799900.SGD","BK4559","IE00B2B36J28.USD","LU0345769631.USD","LU0203347892.USD","LU1074936037.SGD","JNJ","LU1066053197.SGD","LU1914381329.SGD","IE00BFTCPJ56.SGD","SG9999002224.SGD","IE00B1BXHZ80.USD","LU0792757196.USD","LU2112291526.USD","LU0203345920.USD","LU1162221912.USD","SG9999001440.SGD","BK4007","LU1585245621.USD","SG9999002232.USD","LU1506573853.SGD","IE00B3PB1722.GBP","LU1023059063.AUD","LU1244550494.USD","NMRA","LU1894683264.USD","LU0882574055.USD","BK4568","LU0289739699.SGD","LU1244550221.USD","LU1196500208.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","LU0058720904.USD","IE00B42XCP33.USD","LU0345770308.USD","LU1280957306.USD","IE00BVYPNW00.USD","LU0466842654.USD","LU0345770993.USD","LU2129689431.USD","BK4550","IE00B19Z3B42.SGD","LU1032466523.USD","LU1066051225.USD"],"gpt_icon":0},{"id":"2517313024","title":"Stock Market Drama Highlights Trump's Game Of Chicken With Economy","url":"https://stock-news.laohu8.com/highlight/detail?id=2517313024","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517313024?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352425,"startTime":"0","endTime":"0","summary":"Uncertainty socked the U.S. stock market in February, short-circuiting an early-year rally and saddling fund investors with losses.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/etfs-and-funds/mutual-funds/stock-market-drama-highlights-trumps-game-of-chicken-with-economy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU2108987350.USD","MCD","UBmain","LVHD","GOVT","BND","IBM","JNJ","EUFN","US6M.BOND","VTI","ZFmain","SHY","DRAG","ZBmain","US10Y.BOND","SHLD","IEI","TNmain","IEF","US5Y.BOND","LU1917777945.USD","LU0320765646.SGD","LU1244550494.USD","LU1880398554.USD","BK4568","LU0289739699.SGD","SG9999014575.USD","VTI.AU","IE00BJTD4V19.USD","LU2362541513.USD","US2Y.BOND","LU1244550221.USD","US30Y.BOND","FDN","FDL","LU0058720904.USD","CQQQ","US3Y.BOND","ZTmain","LU0345770993.USD","US12M.BOND","US7Y.BOND","LU1267930730.SGD","IYK"],"gpt_icon":1},{"id":"2517480505","title":"InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480505?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"JENA, Germany, March  07, 2025  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038913/0/en/InflaRx-Showcases-Vilobelimab-s-Role-in-Immuno-Dermatology-at-the-2025-AAD-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","LU1066051498.USD","BK4018","LU2129689431.USD","LU2129689514.USD","BK4139","BK4558","LU2552382215.SGD","PD","PG","ARDS","IE00BLSP4239.USD","SG9999002232.USD","LU1868836914.USD","LU0234572021.USD","USA","BK4568","LU1066053197.SGD","SG9999014542.SGD","SG9999001440.SGD","LU0094547139.USD","LU1169589451.USD","SG9999014575.USD","BK4504","BK4535","BK4181","LU0061475181.USD","LU1929549753.HKD","BNTX","BK4534","BK4559","IE00B3T34201.USD","IE00BWXC8680.SGD","LU1868837136.USD","IE00BBT3K403.USD","LU0868494617.USD","LU1162221912.USD","LU1430594728.SGD","SG9999015341.SGD","LU1868837300.USD","SG9999015358.SGD","LU1585245621.USD","PK","SG9999002224.SGD","LU1868836591.USD","BK4581","SG9999014567.USD","LU0234570918.USD","BK4533","LU0689626769.HKD"],"gpt_icon":0},{"id":"2517633487","title":"Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2517633487","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517633487?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:55","pubTimestamp":1741352147,"startTime":"0","endTime":"0","summary":"Astrazeneca (AZN) said Friday that results from a phase 3 trial of Imfinzi in combination with standard-of-care chemotherapy to treat certain gastric cancers met the primary endpoint of event-free sur","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4585","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","BK4007","LU0320765992.SGD","LU2417539215.USD","LU0109394709.USD","BK4588","LU2236285917.USD","BK4568","AZN"],"gpt_icon":0},{"id":"2517388304","title":"AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517388304","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517388304?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:54","pubTimestamp":1741352061,"startTime":"0","endTime":"0","summary":"On Friday, AstraZeneca Plc  released high-level results from the MATTERHORN Phase 3 trial evaluatingImfinzi as a perioperative treatment for patients with resectable Stage II-IVA gastric and gastroesophageal junction  cancers.The trial showed that perioperative treatment with Imfinziin combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival .Also Read: AstraZeneca’s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal junction  cancers.A strong trend was observed for the secondary endpoint of overall survival  in favor of theImfinzi-based regimen. The trial will follow OS, which will be formally assessed at the final analysis.Gastric cancer is the fifth leading cau","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-based-regimen-shows-125421014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0320765992.SGD","LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","LU2417539215.USD","BK4588","LU2456880835.USD","OS","AZN","SSI","LU2462157665.USD","LU0889565916.HKD","BK4568","BK4585","BK4097"],"gpt_icon":0},{"id":"2517480086","title":"2 Dependable Dividend Stocks That Can Pay You for Life","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480086","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480086?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:15","pubTimestamp":1741349700,"startTime":"0","endTime":"0","summary":"Medtronic and Abbott Labs have raised their dividends for a combined 99 years.Both healthcare giants have solid operations and excellent long-term prospects.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/07/2-dependable-dividend-stocks-that-can-pay-you-for/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU2089984988.USD","BK4592","LU0170899867.USD","SG9999004303.SGD","LU2468319806.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4533","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU1721429402.USD","SG9999002232.USD","ABT","IE00B4R5TH58.HKD","LU1989763690.USD","IE00BJJMRZ35.SGD","LU0234572021.USD","LU2133065610.SGD","BK4082","LU1057294990.SGD","LU1691799644.USD","LU1989763427.SGD","IE0002141913.USD","SG9999002224.SGD","LU1023059063.AUD","LU0122379950.USD","LU1721429741.USD","BK4585","LU2237957902.USD","BK4588","IE0009355771.USD","LU2237957811.SGD","BK4568","SGXZ23171101.USD","LU0868494617.USD","LU1914381329.SGD","LU2112291526.USD","BK4566","BK4504","BK4581","LU0266013472.USD"],"gpt_icon":0},{"id":"2517484555","title":"AstraZeneca announces MATTERHORN trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517484555","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517484555?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:07","pubTimestamp":1741349232,"startTime":"0","endTime":"0","summary":"Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FL...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-matterhorn-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-matterhorn-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","LU0889565916.HKD","LU2456880835.USD","BK4585","LU0320765992.SGD","BK4588","BK4568","LU2236285917.USD","LU2417539215.USD","BK4007","LU1829250122.USD","LU0109394709.USD","AZN"],"gpt_icon":0},{"id":"2517816524","title":"Advantage Solutions Reports Fourth Quarter and 2024 Results: Transformation Initiatives Continue to Strengthen the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2517816524","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517816524?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"Delivered Adjusted EBITDA growth through strong execution and cost discipline Continued progress on the transformation to enhance capabilities and increase operating efficiencies Management expects gr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038854/0/en/Advantage-Solutions-Reports-Fourth-Quarter-and-2024-Results-Transformation-Initiatives-Continue-to-Strengthen-the-Company.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4009","BK4551","BK4588","BK4535","BNTX","BK4139","BK4548","ADV","BK4568","BK4585"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4156","BK4582","BK4132","FLOT","LU2417539215.USD","OS","ALK","AZN","BK4007","LU0320765992.SGD","BK4588","TEN","BK4008","HCC","BK4213","BK4124","BTC","BK4144","LU2462157665.USD","BK4585","LU0889565916.HKD","BK4568","LU2456880835.USD","VOD","BK4500","LU2236285917.USD","HSCT","LU0109394709.USD","BK4532","BK4097","BK4006","CRT","LU1829250122.USD"],"gpt_icon":0},{"id":"2517113485","title":"AstraZeneca’s MATTERHORN Phase III trial showed improvement in endpoint of EFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2517113485","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517113485?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:12","pubTimestamp":1741345966,"startTime":"0","endTime":"0","summary":"Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazenecas-matterhorn-phase-iii-trial-showed-improvement-in-endpoint-of-efs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazenecas-matterhorn-phase-iii-trial-showed-improvement-in-endpoint-of-efs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","III","LU0889565916.HKD","LU2456880835.USD","BK4134","BK4585","LU0320765992.SGD","BK4588","BK4568","LU2236285917.USD","LU2417539215.USD","BK4007","LU1829250122.USD","LU0109394709.USD","AZN"],"gpt_icon":0},{"id":"2517810091","title":"Berenberg Bank Remains a Hold on Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517810091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517810091?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:38","pubTimestamp":1741343910,"startTime":"0","endTime":"0","summary":"In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/berenberg-bank-remains-a-hold-on-pfizer-pfe-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/berenberg-bank-remains-a-hold-on-pfizer-pfe-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0225284248.USD","SG9999011175.SGD","BK4533","LU0868494617.USD","LU0289739699.SGD","LU1883839398.USD","LU0225771236.USD","SG9999002224.SGD","LU0058720904.USD","BK4585","IE000M9KFDE8.USD","LU1066053197.SGD","LU1023059063.AUD","PFE","IE00BBT3K403.USD","IE00B19Z3B42.SGD","LU0321505868.SGD","SG9999003800.SGD","LU0456855351.SGD","SG9999013999.USD","BK4599","IE0002270589.USD","LU0306807586.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","SG9999002232.USD","LU0985481810.HKD","BK4581","LU1057294990.SGD","LU0234572021.USD","SGXZ57979304.SGD","BK4550","BK4592","BK4534","LU0306806265.USD","LU1894683264.USD","LU0321505439.SGD","LU1894683348.USD","IE00B19Z3581.USD","LU0170899867.USD","BK4568","SG9999001176.USD","LU0122379950.USD","LU1066051498.USD","SG9999001176.SGD","BK4588"],"gpt_icon":0},{"id":"2517100982","title":"Legal Challenges and Financial Risks Prompt Sell Rating for Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2517100982","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517100982?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:26","pubTimestamp":1741343163,"startTime":"0","endTime":"0","summary":"Analyst David Risinger of Leerink Partners reiterated a Sell rating on Moderna (MRNA – Research Report), with a price target of $27.00. David Risin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/legal-challenges-and-financial-risks-prompt-sell-rating-for-moderna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/legal-challenges-and-financial-risks-prompt-sell-rating-for-moderna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4139","BK4548","BK4588","BK4551","BK4501","BK4532","BK4585","BK4533","MRNA","BK4568"],"gpt_icon":0},{"id":"2517101929","title":"Warburg Research Remains a Buy on Deutsche Pfandbriefbank (0R9K)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517101929","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517101929?lang=en_us&edition=fundamental","pubTime":"2025-03-07 17:39","pubTimestamp":1741340342,"startTime":"0","endTime":"0","summary":"In a report released today, Andreas Plaesier from Warburg Research maintained a Buy rating on Deutsche Pfandbriefbank (0R9K – Research Report), wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/warburg-research-remains-a-buy-on-deutsche-pfandbriefbank-0r9k-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/warburg-research-remains-a-buy-on-deutsche-pfandbriefbank-0r9k-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BNTX","PBBGF","BK4568","BK4548","BK4139","BK4535","BK4551","BK4195","BK4229"],"gpt_icon":0},{"id":"2517106220","title":"The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2517106220","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517106220?lang=en_us&edition=fundamental","pubTime":"2025-03-07 15:59","pubTimestamp":1741334340,"startTime":"0","endTime":"0","summary":"Chicago, IL – March 7, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Jazz Pharmaceuticals JAZZ, Chimerix CMRX, Moderna MRNA, GSK plc GSK and Regeneron Pharmaceuticals, Inc. REGN.Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced an agreement to acquire Chimerix. Meanwhile, other pipeline and regulatory updates were in focus.Shares of clinical-stage biotech Chimerix skyrocketed following an acquisition agreement from Jazz Pharmaceuticals for $8.55 per share in cash, aggregating to nearly $935 million.The offer price reflects an approximately 72% premium based on CMRX’ closing price on Tuesday.The BLA is seeking approval of the candidate as an add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-jazz-pharmaceuticals-075900590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU0321505439.SGD","LU0456855351.SGD","LU0170899867.USD","LU0321505868.SGD","LU2362541273.HKD","LU2023250504.SGD","IE00BLSP4452.SGD","LU0985481810.HKD","LU0306806265.USD","LU0114720955.EUR","LU2089984988.USD","SGXZ57979304.SGD","BK4534","LU0058720904.USD","LU0868494617.USD","BK4533","BK4551","SG9999003800.SGD","SG9999001176.USD","LU0234572021.USD","GSK.UK","LU0882574055.USD","LU2468319806.SGD","LU0320765992.SGD","LU1066051498.USD","SG9999011175.SGD","REGN","IE00BBT3K403.USD","MRNA","LU1917777945.USD","GSK","SG9999013999.USD","JAZZ","LU0306807586.USD","LU2362541513.USD","BK4585","BK4550","BK4532","IE00B19Z3B42.SGD","IE00BN0W2W23.USD","CMRX","BK4568","LU1974910355.USD","BK4007","LU0889565916.HKD","LU0122379950.USD","LU0225771236.USD","LU0109394709.USD"],"gpt_icon":1},{"id":"2517172911","title":"The Smartest Dividend Stocks to Buy With $2,000 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2517172911","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517172911?lang=en_us&edition=fundamental","pubTime":"2025-03-07 15:15","pubTimestamp":1741331700,"startTime":"0","endTime":"0","summary":"There are lots of good dividend stocks to consider stepping into here, but only a few truly great income-producing prospects.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/07/the-smartest-dividend-stocks-to-buy-with-2000-righ/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0122379950.USD","SG9999003800.SGD","LU0985481810.HKD","LU0170899867.USD","SG9999013999.USD","LU0306807586.USD","LU1894683264.USD","LU0306806265.USD","LU1883839398.USD","BK4585","IE0002270589.USD","BK4550","SG9999001176.SGD","BK4588","IE00B19Z3B42.SGD","SG9999002224.SGD","LU1894683348.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU0225284248.USD","BK4534","IE00BLSP4452.SGD","LU0321505868.SGD","LU1066053197.SGD","PFE","BK4581","SG9999011175.SGD","LU1023059063.AUD","LU0058720904.USD","SG9999001176.USD","LU0225771236.USD","SGXZ57979304.SGD","BK4533","BK4599","BK4007","LU0321505439.SGD","SG9999002232.USD","LU0289739699.SGD","BK4568","BK4592","LU1066051498.USD","LU0868494617.USD","LU0456855351.SGD"],"gpt_icon":1}],"pageSize":16,"totalPage":19,"pageCount":3,"totalSize":299}]}}